Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (12 total)
-
Creator: ACTT- Study Group
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2022-05-23
Description: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to… -
Creator: Normand, Sharon-Lise T.
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2020-07-21
Description: In a platform trial, patients with a single disease are randomly assigned to a group of different therapies on the basis of a decision algorithm to determine whether any therapy has benefit. -
Creator: Chappell, Keith J., Francesca L. Mordant, Zheyi Li, Danushka K. Wijesundara, Paula Ellenberg, Julia A. Lackenby, Stacey T. M. Cheung, Naphak Modhiran, Michael S. Avumegah, Christina L. Henderson, Kym Hoger, Paul Griffin, Jillian Bennet, Luca Hensen,…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-19
Description: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential… -
Creator: Ella, Raches, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-08
Description: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled… -
Creator: the Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-19
Description: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. -
Creator: Boulware, David R., Matthew F. Pullen, Ananta S. Bangdiwala, Katelyn A. Pastick, Sarah M. Lofgren, Elizabeth C. Okafor, Caleb P. Skipper, Alanna A. Nascene, Melanie R. Nicol, Mahsa Abassi, Nicole W. Engen, Matthew P. Cheng, Derek LaBar, Sylvain A.…
Subject: Research
Item Type: Publication
Date Last Updated: 2020-08-06
Description: This reports on a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. -
Creator: Zhu, Feng-Cai, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Bei-Fang Yang, Ling Wang, Wen-Juan Wang, Shi-Po Wu, Zhao Wang, Xiao-Hong Wu, Jun-Jie Xu, Zhe Zhang, Si-Yue Jia, Bu-Sen Wang, Yi Hu, Jing-Jing Liu, Jun Zhang,…
Subject: Research
Item Type: Publication
Date Last Updated: 2020-07-20
Description: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an… -
Creator: Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-07-20
Description: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of… -
Creator: The RECOVERY Collaborative Group.
Subject: Research
Item Type: Publication
Date Last Updated: 2020-07-17
Description: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. -
Creator: Playford, E. G., T. Munro, S. M. Mahler, S. Elliott, M. Gerometta, K. L. Hoger, M. L. Jones, P. Griffin, K. D. Lynch, H. Carroll, D. El Saadi, M. E. Gilmour, B. Hughes, K. Hughes, E. Huang, C. de Bakker, R. Klein, M. G. Scher, I. L. Smith, L. F.…
Subject: Laboratory
Item Type: Publication
Date Last Updated: 2020-04
Description: The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults.